Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

ABT-530

- PMLiVE

AbbVie’s long-term Rinvoq data shows continued repigmentation in non-segmental vitiligo

The use of Rinvoq in non-segmental vitiligo is under regulatory review by the US FDA

- PMLiVE

Pfizer’s Litfulo significantly improved repigmentation in nonsegmental vitiligo

NSV is a chronic autoimmune disease where the immune system attacks melanin-producing cells, leading to a loss of pigment

- PMLiVE

Biogen announces phase 2 data for cutaneous lupus erythematosus

The results for litifilimab support the potential to achieve rapid and durable improvements in skin disease activity

People smiling in meeting

Invited, but not equipped: patient involvement needs more than an open door

Explore how pharma can help patients and patient organisations prepare for meaningful involvement in EU HTA without shaping their contribution.

Cuttsy + Cuttsy

HCP engaging with elderly patient

Long-term clinical trial engagement is a behavioural challenge – not just an informational one

Explore why long-term clinical trial engagement is a behavioural challenge, showing how proactive support from site teams can help participants stay connected, confident and committed throughout a study.

Cuttsy + Cuttsy

Doctor sitting with patient

Patients are telling the truth — just not to you

Patients are often most honest outside the clinic—revealing vital insights that can help clinical trial teams build trust, improve participation and collect better data.

Cuttsy + Cuttsy

- PMLiVE

Gilead and PAHO announce milestone partnership to accelerate access to HIV pre-exposure treatment

The agreement will improve access to twice-yearly Lenacapavir across Latin America and the Caribbean

Group of women smiling

When what matters to patients is hard to measure

Patient-relevant outcomes sit at the heart of the EU HTA reforms, but ensuring they reflect lived experience requires you to look beyond what traditional clinical endpoints measure.

Cuttsy + Cuttsy

- PMLiVE

Gilead opens new research centre bringing together oncology, inflammation and research data science teams

The centre in California supports the company’s $32bn US investment

- PMLiVE

Novartis announces trial results for remibrutinib in relapsing multiple sclerosis

MS affects nearly three million people worldwide and has three main types

- PMLiVE

AbbVie’s Rinvoq approved by European Commission for non-segmental vitiligo

Rinvoq is the first and only systemic medication approved in the EU for NSV

- PMLiVE

Pfizer announces phase 3 results for nonsegmental vitiligo treatment

Litfulo delivered significant, clinically meaningful improvements for both face and body

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links